A Phase II Study of Amivantamab and Lazertinib to Treat Non-Small Cell Lung Cancer that Spread to the Brain

Share
Print

Full Title

A Phase 2 Single-Arm Study of Amivantamab (JNJ-61186372) and Lazertinib in metastatic EGFR-mutant Lung Cancer with Progressive or New CNS Metastases on Previous Treatment

Purpose

This study is evaluating amivantamab and lazertinib to treat non-small cell lung cancer (NSCLC) that spread to the brain or spinal cord. Researchers are assessing the safety and effectiveness of this therapy. The cancer must also have a change (mutation) in the EGFR gene.

Both amivantamab and lazertinib target cancer cells with an EGFR mutation. Researchers will see if these two drugs can stop or slow the growth of cancer cells. Lazertinib is taken orally (by mouth) and amivantamab is given as intravenously (by vein).

 

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have advanced NSCLC that has an EGFR mutation. The cancer must have spread to the brain or the lining of the brain and spinal cord after treatment.
  • Any radiation therapy must finish at least 1 week before the study treatment starts.
  • Any chemotherapy must finish at least 2 weeks before the study treatment starts.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Helena Yu at 646-608-3912.

Protocol

21-144

Phase

II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators